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ABSTRACT
Background and aim Thymus-derived regulatory
T cells (Tregs) mediate dominant peripheral tolerance and
treat experimental colitis. Tregs can be expanded from
patient blood and were safely used in recent phase 1
studies in graft versus host disease and type 1 diabetes.
Treg cell therapy is also conceptually attractive for
Crohn’s disease (CD). However, barriers exist to this
approach. The stability of Tregs expanded from Crohn’s
blood is unknown. The potential for adoptively
transferred Tregs to express interleukin-17 and exacerbate
Crohn’s lesions is of concern. Mucosal T cells are
resistant to Treg-mediated suppression in active CD. The
capacity for expanded Tregs to home to gut and lymphoid
tissue is unknown.
Methods To deﬁne the optimum population for Treg
cell therapy in CD, CD4+CD25+CD127loCD45RA+ and
CD4+CD25+CD127loCD45RA− Treg subsets were isolated
from patients’ blood and expanded in vitro using a
workﬂow that can be readily transferred to a good
manufacturing practice background.
Results Tregs can be expanded from the blood of
patients with CD to potential target dose within
22–24 days. Expanded CD45RA+ Tregs have an
epigenetically stable FOXP3 locus and do not convert to
a Th17 phenotype in vitro, in contrast to CD45RA− Tregs.
CD45RA+ Tregs highly express α4β7 integrin, CD62L and
CC motif receptor 7 (CCR7). CD45RA+ Tregs also home
to human small bowel in a C.B-17 severe combined
immune deﬁciency (SCID) xenotransplant model.
Importantly, in vitro expansion enhances the suppressive
ability of CD45RA+ Tregs. These cells also suppress
activation of lamina propria and mesenteric lymph node
lymphocytes isolated from inﬂamed Crohn’s mucosa.
Conclusions CD4+CD25+CD127loCD45RA+ Tregs may
be the most appropriate population from which to
expand Tregs for autologous Treg therapy for CD, paving
the way for future clinical trials.
INTRODUCTION
Thymically derived FOXP3+ regulatory T cells
(Tregs) are key mediators of peripheral tolerance
and are likely to have a role in preventing inappro-
priate mucosal inﬂammation in response to bacter-
ial, and other, luminal antigens. In mice, Treg
depletion impairs oral tolerance.1 Adoptively trans-
ferred Tregs prevent the onset of colitis or treat estab-
lished colitis in a number of murine models.2–7
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Signiﬁcance of this study
What is already known on this subject?
▸ Thymically derived regulatory T cells (Tregs) can
modulate effector immune responses and,
when expanded in vitro, have recently shown
promise for graft versus host disease and type
1 diabetes in humans, leading to interest in
this therapeutic approach for Crohn’s disease.
▸ Barriers to autologous Treg therapy in Crohn’s
include the requirement for in vitro expansion
to a target dose, potential Treg plasticity to
pathogenic interleukin-17+ cells, uncertain
homing to mucosal tissue and effector T cell
resistance to Treg-mediated suppression in
inﬂamed Crohn’s mucosa.
▸ Initial enrichment on the basis of CD45RA+
expression can improve the phenotypic stability
of an expanded Treg population obtained from
healthy control blood, but the value of this
approach in Crohn’s disease is unknown.
What are the new ﬁndings?
▸ We show that it is technically feasible to
expand functional Tregs to numbers consistent
with a target dose from the blood of patients
with Crohn’s disease.
▸ In vitro expansion enhances the in vitro
suppressive activity of these cells. Expanded
Tregs suppress activation of lamina propria and
mesenteric lymph node lymphocytes isolated
from inﬂamed Crohn’s mucosa.
▸ In contrast to Tregs expanded from CD45RA
−
precursors, expanded CD45RA+ Tregs have
epigenetically stable FOXP3 expression and are
resistant to Th17 conversion.
▸ Expanded CD45RA+ Tregs also express α4β7
integrin, CD62L and CCR7, and home to
human small bowel in a SCID mouse bearing
subcutaneously implanted human intestine.
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FOXP3 mutations lead to multisystem autoimmunity with enter-
opathy in mice and humans.8 9 Disruption of other key mole-
cules implicated in Treg function, such as transforming growth
factor (TGF)-β, Cytotoxic T Lymphocyte-Associated (CTLA)-4,
interleukin (IL)-10R subunits, IL-2 or its receptor subunits, is
associated with autoimmunity and intestinal inﬂammation.10
Human peripheral blood (PB) or umbilical cord blood Tregs
can be expanded in vitro through T cell receptor (TCR)
stimulation in the presence of IL-2.11–26 In vitro expanded
human Tregs prevent transplant rejection,
27 28 transplant
arteriosclerosis29 and graft versus host disease (GvHD)21 30 in
humanised mice. Promisingly, recent phase 1 clinical trials
have shown Treg cell therapy to be safe in patients with
GvHD12 24 and type 1 diabetes.18 Additional phase 1 studies
have started in renal (the ONE study) and liver transplant-
ation (ThRIL study).19 31
Lamina propria (LP) Tregs are increased in the mucosa of
patients with active Crohn’s disease (CD) and decreased in
blood, compared with healthy controls.32–34 LP Tregs obtained
from inﬂamed CD mucosa suppress proliferation of conventional
CD4+CD25lo/int T cells (Tcon) obtained from blood but not LP
Tcons,
35 suggesting that mucosal Tcons in active CD may be resist-
ant to Treg-mediated suppression. LP Tcons from CD mucosa over-
express Smad7, an inhibitor of TGF-β signalling, which confers
resistance to Treg-mediated suppression.
35 36 Activated Tcons also
have an effector-memory phenotype, conferring relative resist-
ance to Treg-mediated suppression.
37 However, Tregs expanded in
vitro in the presence of rapamycin from the PB of patients with
end-stage renal failure (ESRF), systemic lupus erythematosus
(SLE), rheumatoid arthritis (RA), multiple sclerosis (MS) and
asthma are more suppressive than freshly isolated Tregs obtained
from the same donor.26 38 If it can be shown that in vitro expan-
sion enhances the suppressive ability of CD PB Tregs and that
these expanded cells suppress mucosal inﬂammation, parenteral
therapy with autologous in vitro expanded Tregs generated from
CD PB would become a conceptually attractive approach to
induce remission in active CD.
IL-17 contributes to mucosal homoeostasis but has also been
implicated in the pathogenesis of CD. Tregs isolated from
healthy donor PB or tonsils can be induced to express IL-17
and the Th17 transcription factor RORC when activated in
vitro in the presence of IL-1, IL-2, IL-21 and IL-23.39–42
Although major sources of IL-17 in the gut include Tcons and γδ
T cells, a proportion of Tregs obtained from inﬂamed CD
mucosa co-express FOXP3 and IL-17.43 Th1 Treg plasticity has
also been described in vitro and in vivo.44 45 In humans,
phenotypically distinct Treg populations can be delineated
on the basis of CD45RA expression.17 46 ‘Resting’
CD4+CD25hiCD127loCD45RA+ Tregs (rTregs) are resistant to
induction of IL-17 and interferon (IFN)-γ in vitro.46 In contrast,
‘activated’ CD4+CD25hiCD127loCD45RA− Tregs (aTregs) can be
induced to express IL-17 and IFN-γ in vitro.46 Similarly,
Tregs expanded from healthy donor CD45RA
+ Tregs (in the
absence of rapamycin) do not contain cytokine producers and
are highly suppressive, while Tregs expanded from CD45RA
−
Tregs express proinﬂammatory cytokines and lose FOXP3 expres-
sion with repetitive stimulation in vitro.17 47 Tregs expanded
from healthy control CD45RA− precursors (but not CD45RA+
precursors) also have stimulation-induced demethylation of
RORC, which may be permissive for IL-17 expression.48
Furthermore, imprinting α4β7 integrin expression on in vitro
expanded Tregs by supplementing culture with all-trans retinoic
acid (ATRA) results in high IL-17 expression.21 Even though
IL-17+ Tregs isolated from human blood and tonsil retain their
suppressive ability in vitro,39–41 the potential for adoptively
transferred Tregs to exacerbate inﬂammation in CD lesions
through the production of proinﬂammatory cytokines is of sig-
niﬁcant concern.
Using cell enrichment strategies achievable with currently
available good manufacturing practice (GMP) technologies, we
show that initial enrichment on the basis of CD45RA+ expres-
sion is required to generate a homogenous and epigenetically
stable Treg population following expansion, in the presence of
rapamycin, from the PB of patients with CD. These cells are
resistant to Th17 plasticity, express lymphoid and gut homing
markers, and home to human gut following adoptive transfer to
a SCID mouse bearing subcutaneously implanted human small
bowel (SB). In vitro expansion also enhances the suppressive
ability of these cells, licensing them to suppress activation of LP
and mesenteric lymph node (MLN) Tcons obtained from
inﬂamed CD resection specimens. These data suggest that CD
PB CD4+CD25hiCD127loCD45RA+ cells may be the most
appropriate population from which to expand Tregs in vitro for
forthcoming clinical trials of autologous Treg cell therapy in CD.
MATERIALS AND METHODS
Patient samples
Following Institutional Review Board (IRB) approval (SE
London REC 2; 10/H0804/65 and East London REC 2 (10/
H0704/74)), patients with CD attending Guy’s & St Thomas’
National Health Service (NHS) Foundation Trust and Bart’s
Health NHS Trust were invited to donate blood and/or resected
tissue. Prospective written consent was obtained. Demographic
details are shown in table 1.
Treg enrichment and sorting
Online supplementary ﬁgure S1 illustrates the experimental
design. Peripheral blood mononuclear cells (PBMCs) were iso-
lated by density gradient centrifugation over lymphocyte separ-
ation medium (LSM) 1077 and CD4+ lymphocytes enriched to
>95% by positive magnetic activated cell separation (MACS)
selection (Miltenyi, Bergisch-Gladbach, Germany). Lymphocytes
were labelled using the ‘Human Regulatory T Cell Sorting Kit’
(BD Biosciences, San Diego, California, USA), as described pre-
viously,25 and sorted to CD4+CD25hiCD127loCD45RA+ and
CD4+CD25hiCD127loCD45RA− Treg subsets, and autologous
CD4+CD25− Tcons on a FACSAria (BD; see online supplemen-
tary ﬁgure S2A–D). Median (IQR) postsort purity was 86.5%
(80.8–91.6%; n=13) for CD4+CD25hiCD127loCD45RA+ Tregs
(CD45RA+ Tregs) and 92.7% (87.7–94.9%; n=13) for
CD4+CD25hiCD127loCD45RA− Tregs (CD45RA
− Tregs).
Autologous Tcons were stored at −80°C.
Signiﬁcance of this study
How might it impact on clinical practice in the
foreseeable future?
▸ These results demonstrate that initial Treg enrichment on the
basis of CD45RA+ expression is required to produce a
phenotypically stable and suppressive Treg population
following in vitro expansion and that these in vitro
expanded cells have the capacity to home to mucosal tissue,
paving the way for autologous Treg therapy in this
therapeutically challenging disease.
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In vitro generation of Treg lines
Precursor Treg populations were expanded in vitro as described
previously21 25 and described in detail in online supplemental
methods.
Cell surface and intracellular stains
Fluorochrome-conjugated antibodies, buffers and experimental
technique are listed in online supplemental methods.
Assessment of the in vitro suppressive ability of putative Tregs
Assays to determine Treg function in vitro were performed as
described previously,25 49 and described in detail in the online
supplemental methods.
rtPCR
Following total RNA extraction from Trisure (Bioline, London,
UK), cDNA was synthesised using the RevertAid First Strand
cDNA Synthesis Kit and multiplex rtPCR performed in dupli-
cate using the Maxima Probe/ROX qPCR Master Mix (both
Thermo Fischer Scientiﬁc) on a BioRad C1000 Thermal Cycler.
Primers are listed in online supplemental methods.
Estimation of cytokine concentrations
Cytokine concentrations were estimated in culture supernatants
using the Cytometric Bead Array (CBA) Human Th1/Th2/Th17
Cytokine Kit (BD) or sandwich ELISAs (R&D), as indicated.
Assessment of IL-17 production under proinﬂammatory
conditions
In vitro generated Tregs were activated with anti-CD3/anti-CD28
beads at a 1:1 ratio and cultured at 106 cells/mL in complete
Roswell Park Memorial Institute (RPMI) for 5 days at 37°C/5%
CO2, supplemented with the following cytokine cocktails, as
previously described:21 23 39 (A) IL-2 (10 IU/mL, Proleukin);
(B) IL-2, IL-1 (10 ng/mL), IL-6 (4 ng/mL) and TGF-β (5 ng/mL);
(C) IL-2, IL-21 (25 ng/mL), IL-23 (25 ng/mL) and TGF-β (all
R&D Systems). Supernatant IL-17 concentrations were mea-
sured by ELISA.
Assessment of FOXP3 promoter demethylation
Genomic DNA was isolated using a ‘DNeasy kit’ (Qiagen,
Manchester, UK). Bisulﬁte conversion and assessment of the
methylation status of the FOXP3 Treg-speciﬁc demethylated
region (TSDR) was performed by Epiontis.50 51 The genomic
locations of FOXP3 and GAPDH CpG-rich regions probed have
been reported.51
Isolation of LP mononuclear cells and MLN mononuclear
cells
LP mononuclear cells (LPMCs) and MLN mononuclear cells
(MLNMCs) were isolated as described previously52 and listed in
online supplemental methods.
C.B-17 SCID mouse human intestinal xenotransplant model
Experimental design is illustrated in ﬁgure 3C. The C.B-17 SCID
mouse human intestinal xenotransplant model has been
described previously53 54 and is described in detail in online sup-
plemental methods. IRB and IACUC approvals were obtained
prospectively (Ethics Committee for Animal Experimentation,
Hebrew University of Jerusalem; MD-11-12692-4 and the
Helsinki Committee of the Hadassah University Hospital; 81-23/
04/04). Techniques for the detection of adoptively transferred
Tregs are also described in detail in online supplemental methods.
Statistical analysis
Statistical analysis was carried out using GraphPad Prism 5
(GraphPad Software Inc, La Jolla, California, USA) and the
methods used are described in detail in the online supplemental
methods.
RESULTS
Tregs can be expanded from the blood of patient with CD
using GMP-compatible protocols
Hoffmann et al17 showed that initial Treg enrichment on the
basis of CD45RA+ expression was required to expand homo-
genous and stable Treg lines from healthy donors in the absence
of supplemental rapamycin. Rapamycin prevents the outgrowth
of contaminating Tcons in Treg cultures, and may make the
requirements for the starting population less strin-
gent.11 13 15 21 23 55 However, the optimum precursor popula-
tion from which to expand a homogenous, suppressive and
epigenetically stable Treg population from CD PB is currently
unknown. In previous studies, we accomplished in vitro expan-
sion of in vitro suppressive Tregs from healthy controls
21 and
renal transplant candidates.26 We sought to determine if Tregs
could be expanded in vitro from the blood of patients with CD.
Freshly isolated CD4+ lymphocytes from 13 patients with
CD were ﬂuorescence-activated cell sorting (FACS)-sorted into
CD4+CD25hiCD127loCD45RA+ (median (IQR) of 2200 cells/
mL PB (860–4400)) and CD4+CD25hiCD127loCD45RA−
subsets (3700 cells/mL (2000–4500)), then expanded in vitro in
the presence of high-dose IL-2, rapamycin and anti-CD3/
anti-CD28 beads. Active disease, evidenced by a Harvey
Bradshaw Index >5 (n=4) or elevated C reactive protein (n=1),
was not associated with a signiﬁcantly reduced yield (see online
supplementary ﬁgure S2E). Donor clinical characteristics are
given in table 1.
Table 1 Demographic details of study patients
Female sex 6 (46.1%)
Age (mean±SD) 42.6 (±13.0)
Disease duration 15.4 (±10.4)
Age at diagnosis (mean±SD) 27.7 (±13.1)
Diagnosis <16 years old (A1) 2 (15.4%)
Diagnosis 17–40 years old (A2) 9 (69.2%)
Diagnosis >40 years old (A3) 2 (15.4%)
Location
Ileal only (L1) 1 (7.7%)
Colonic only (L2) 4 (30.8%)
Ileo-colonic (L3) 8 (61.5%)
Concomitant upper GI disease (L4) 2 (15.4%)
Perianal disease (p) 2 (15.4%)
Behaviour
Inflammatory (B1) 9 (69.2%)
Stricturing (B2) 2 (15.4%)
Penetrating (B3) 2 (15.4%)
HBI (median, range) 0 (0–7)
Active disease HBI ≥5 4 (30.8%)
Previous surgery 8 (61.5%)
Medications
Thiopurines 7 (53.8%)
Biologics 4 (30.8%)
Others 3 (23.1%)
GI, gastrointestinal; HBI, Harvey Bradshaw Index.
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Every CD45RA+ Treg line proliferated, to a median (IQR) of
175-fold (66–531; n=13) at D24 (ﬁgure 1A). In contrast, 3 of
13 (23%) CD45RA− Treg lines did not proliferate and were dis-
continued. CD45RA− Tregs expanded 130-fold (8–209; n=10).
Expanded Tregs were exclusively CD4
+ lymphocytes. Expression
of CD25 and FOXP3 was comparable in D24 CD45RA+ and
CD45RA− Tregs (ﬁgure 1B), but a greater proportion of
CD45RA+ Tregs maintained a CD4
+CD25hiCD127loFOXP3+
phenotype (p=0.037; ﬁgure 1C).
Proliferation assays were performed to determine if in vitro
expanded Tregs retained the ability to suppress proliferation of
autologous CD4+CD25− Tcons. CD45RA
+ and CD45RA− Tregs
suppressed Tcon proliferation to an equivalent degree (ﬁgure 1D–E),
demonstrating speciﬁc suppression (vs the 2X cell density
control) above an 8:1 Tcon:Treg ratio. CD45RA
+ and CD45RA−
Tregs reduced IL-2 expression in 96 h co-culture supernatants
(see online supplementary ﬁgure S3A). CD45RA+ Tregs also
suppressed IFN-γ expression in 96 h co-culture supernatants
(see online supplementary ﬁgure S3B).
In vitro expanded CD45RA+ Tregs are resistant to IL-17
induction and stably express FOXP3
The ‘inﬂammatory potential’ of in vitro expanded Tregs
from patients with CD was examined. Genes important in
Figure 1 Expansion, phenotype and potency of in vitro expanded Tregs. (A) Cumulative fold expansion of Treg lines at days 12 and 24 of culture,
grouped according to CD4+CD25hiCD127loCD45RA+ or CD4+CD25hiCD127loCD45RA− precursors; n=13 each, bar: median. (B) Representative FACS
plots gated on live events showing CD25 and FOXP3 expression at D24. (C) Proportion of Tregs with a CD4
+CD25hiCD127lo Treg phenotype at D24.
(D) Representative plots from a proliferation assay, illustrating dose-dependent suppression of Tcon proliferation by CD45RA
+ Tregs. Proliferation
CTV-labelled autologous CD4+CD25− Tcons alone (ﬁlled) or with Tregs at various Tcon:Treg ratios (bold line) is shown. (E) D24 Treg-mediated
suppression of Tcon proliferation. Cumulative data showing mean±SEM suppression seen at each Tcon:Treg ratio. Pooled data from 29 Treg lines.
Comparisons between suppression seen in study conditions and mean non-speciﬁc suppression seen in ‘2X’ control condition (dotted line) are
shown. *p<0.05,***p<0.001 and ****p<0.0001. Tregs, thymus-derived regulatory T cells; FACS, ﬂuorescence-activated cell sorting; Tcons,
conventional CD4+CD25lo/int T cells; CTV, Cell Trace Violet; NS, not signiﬁcant.
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Th17 biology, including RORC, AHR and IL-17, were signiﬁ-
cantly overexpressed in CD45RA− Tregs, in comparison
with expression in paired CD45RA+ Tregs ( p<0.05 for each
comparison, ﬁgure 2A). IL-17 secretion was also signiﬁcantly
different in these Treg subsets. IL-17 expression was
below the limit of detection in 10/11 (91%) CD45RA+
Tregs and signiﬁcantly higher in CD45RA
− Tregs (p=0.02;
ﬁgure 2B).
The potential of in vitro expanded Tregs to turn on an inﬂam-
matory programme following exposure to Th17-inducing cyto-
kines, as occurs in vitro in Tregs isolated from blood,
39–41 was
examined. D24 Tregs were washed and cultured for a further
5 days in the presence of IL-2 alone, or Th17-inducing cyto-
kines (IL-2, IL-1, IL-6 and TGF-β or IL-2, IL-21, IL-23 and
TGF-β; ﬁgure 2C). These proinﬂammatory cytokines failed to
induce IL-17 production by CD45RA+ Tregs. In contrast, IL-17
production by CD45RA− Tregs was 3-fold higher than
CD45RA+ Tregs in neutral conditions (IL-2 alone) and 10-fold
higher in skewing conditions (p<0.001 each comparison).
To ensure that phenotypic stability of CD45RA+ Tregs corre-
lated with an epigenetically stable FOXP3 locus, we determined
the methylation status of the FOXP3 ‘TSDR’ (ﬁgure 2D). We
found the TSDR to be completely demethylated in all
CD45RA+ Treg lines tested (100%; n=9), suggesting an epigen-
etically stable FOXP3 locus in CD45RA+ Tregs even after 24d of
in vitro expansion. In contrast, variable degrees of TSDR
demethylation were seen in CD45RA− Treg lines (median (IQR)
of 90.6% (36.6%–100%); n=6; p=0.008).
In vitro expanded CD45RA+ Tregs express homing receptors
for gut and lymphoid tissue
The ability of in vitro expanded Tregs to home to relevant
immune niches, where they may suppress inﬂammation, is
thought to be critical for cell therapy. Consequently, the expres-
sion of gut homing receptors on in vitro expanded Tregs was
examined by FACS (ﬁgure 3A, B). We found that D24
CD45RA+ Tregs modestly expressed α4β7 integrin and CCR6
(20.8%±7.8% and 12.2%±7.9%, respectively) and did not
express CCR9. Both CD62L (84.8%±20.6%; p=0.04 vs
CD45RA−) and CCR7 (92.1%±12.8%; p=0.03) required for
lymph node homing were more highly expressed in CD45RA+
Tregs than CD45RA
− Tregs. CCR4 (95.4%±4.2%) was also
highly expressed.
Adoptively transferred CD45RA+ Tregs home to inﬂamed
human small intestine in a C.B-17 SCID human SB
xenotransplant model
In view of the favourable phenotype of CD45RA+ Tregs as a can-
didate cell therapy, we next sought to determine whether these
cells could home to inﬂamed human SB in vivo. D24 CD45RA+
Tregs were administered to a C.B-17 SCID mouse bearing
human small intestinal xenotransplants and homing assessed
Figure 2 D24 CD45RA+ Tregs are
resistant to IL-17 induction. (A)
Relative expression of IL17A, RORC
and AHR in D24 CD45RA+ and
CD45RA− Tregs, relative to GAPDH;
n=16, bar at median. (B) D24 Treg
IL-17, IFN-γ and TNF secretion in 24 h
culture supernatants; n=20, bar at
median. (C) IL-17 detected by ELISA
from 5-day culture supernatants of
D24 Tregs cultured in the absence of
rapamycin but with supplemental IL-2
alone, a cocktail of IL-2, IL-1, IL-6 and
TGF-β or a cocktail of IL-2, IL-21, IL-23
and TGF-β. n=17, bar at median. (D)
% FOXP3 TSDR demethylation; n=15,
bar at median. *p<0.05,**p<0.01,
***p<0.001. Tregs, thymus-derived
regulatory T cells; IL, interleukin; IFN,
interferon; TNF, tumour necrosis factor;
TGF, transforming growth factor; TSDR,
Treg-speciﬁc demethylated region; NS,
not signiﬁcant.
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24 h later (ﬁgure 3C, D). Intraluminal injection with entero-
pathogenic Escherichia coli was used to induce mucosal inﬂam-
mation (see online supplementary ﬁgure S4A). Following
adoptive transfer, human CD45+CD3+CD4+ cells were
detected in mouse spleen and inﬂamed human SB LP by FACS
(see ﬁgure 3E; gating strategy online supplementary ﬁgure S4B),
Figure 3 D24 CD45RA+ Tregs express gut and lymphoid homing receptors and home to inﬂamed human LP in a C.B-17 severe combined
immunodeﬁciency (SCID) mouse human intestinal XG model. (A) Representative FACS plots illustrating gut and lymphoid homing receptor expression
on D24 CD45RA+ Tregs (bold line). Gates were drawn on the basis of fully stained CD4
+ lymphocytes (ﬁlled) and ﬂuorochrome minus one (FMO)
controls. (B) Dot plots showing expression of intestinal and lymphoid homing receptors in D24 CD45RA+ and CD45RA− Tregs. n=17; *p<0.05. (C)
Design of the XG mouse experiment. (D) Left panel: mature XGs (circled) are visible subcutaneously on the dorsum of the mouse. Right panel:
dorsal skin has been removed in an anaesthetised mouse to reveal the mucus-ﬁlled XG in situ (right panel). Microscopic images of the XG are
shown in online supplementary ﬁgure S4A. (E) FACS plots showing live human CD45+CD3+CD4+ events in single cell suspensions prepared from
murine spleen, non-inﬂamed and inﬂamed XGs, 24 h after intravenous phosphate buffered saline (PBS) (left panels) or adoptive transfer of Tregs
(right panels). The absolute numbers of CD3+CD4+ events in the XG human CD45+ gates are highlighted. The gating strategy is illustrated in online
supplementary ﬁgure S4B. (F) Immunoﬂuorescence staining of XG cryosections with antihuman CD3 (red), antihuman CD45 (green) and 40,6-
diamidino-2-phenylindole (DAPI) (blue). (E and F) Representative of two independent experiments. Tregs, thymus-derived regulatory T cells; LP, lamina
propria; XG, xenograft; FACS, ﬂuorescence-activated cell sorting; EPEC, enteropathogenic Escherichia coli; NS, not signiﬁcant.
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indicating that adoptively transferred CD45RA+ Tregs homed to
inﬂamed human SB LP in this model. This was conﬁrmed by
the detection of human CD45+CD3+ cells in inﬂamed human
SB LP by immunoﬂuorescence (ﬁgure 3F). We previously
showed that human fetal SB contains a population of
CD3−CD7+ cells that persist following xenotransplantation.53
Human CD45+CD3− events were also detected in non-inﬂamed
human SB LP in both mice that received intravenous PBS and
intravenous Tregs (ﬁgure 3E), suggesting that a population of
long-lived human immune cells was co-transferred with the
human SB transplant.
In vitro expansion enhances the in vitro suppressive ability
of CD45RA+ Tregs
LP Tcons from inﬂamed CD mucosa are resistant to in vitro sup-
pression by autologous LP Tregs.
35 36 Consequently, it is possible
that in vitro expanded Tregs will need an enhanced suppressive
function in order to be successful as a future cell-based therapy.
Expansion with supplemental rapamycin enhances the in vitro
suppressive ability of Tregs from patients with ESRF, SLE, RA,
MS and asthma.26 38 In order to determine if in vitro expansion
enhanced Treg function in patients with CD, freshly isolated
CD4+CD25hiCD127loCD45RA+ Tregs or D24 CD45RA
+ Tregs
that were expanded in vitro from these FACS-sorted
CD4+CD25hiCD127loCD45RA+ precursors were co-cultured
with allogeneic Carboxyﬂuorescein succinimidyl ester
(CFSE)-labelled CD4+CD25− Tcons (n=3 independent
experiments; cells from the same lot of single-donor,
freeze-thawed Tcons for each experiment). D24 CD45RA
+ Tregs
suppressed Tcon proliferation to a greater degree than the freshly
isolated CD4+CD25hiCD127loCD45RA+ Tregs from which they
were expanded, at both a 4:1 and 8:1 Tcon:Treg ratio (p<0.01
and p<0.001, respectively; ﬁgure 4A). This suggests that in
vitro expansion enhances the suppressive ability of D24
CD45RA+ Tregs.
In vitro expanded CD45RA+ Tregs suppress proliferation and
activation of MLN and LP T cells in active CD
We next wished to determine if D24 CD45RA+ Tregs could sup-
press activation and proliferation of Tcons taken from the MLN
and LP of patients with CD (ﬁgure 4B, C). MLNMCs were
co-cultured with Tregs and CD3
+ proliferation assessed at 96 h.
Dose-dependent Treg-mediated suppression of MLN CD3
+ pro-
liferation was seen at each MLNMC:Treg ratio (ﬁgure 4D). We
were unable to demonstrate in vitro suppression of LPMC
CD3+ proliferation with this technique, as both freshly isolated
and freeze-thawed LPMCs obtained from inﬂamed CD mucosa
died prior to acquisition at 96 h (n=4 independent experiments;
see online supplementary ﬁgures S5 and S6).
We recently validated a novel co-culture assay for the assess-
ment of in vitro expanded Treg function. This takes advantage of
Treg-mediated suppression of the early activation marker CD154
(CD40 L) on Tcons at 7 h, which correlates with Treg-mediated
suppression of CFSE dilution and cytokine expression in Tcons
Figure 3 Continued
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Figure 4 In vitro expanded CD45RA+
Tregs suppress CD3
+ T cell responses
from inﬂamed Crohn’s MLN and LP.
(A) Suppression of proliferation of a
single lot of freeze-thawed, allogeneic
Tcons by freshly isolated PB
CD4+CD25hiCD127loCD45RA+ Tregs, or
D24 CD45RA+ Tregs that were
expanded in vitro from these freshly
isolated precursors. Pooled data from
three sets of freshly isolated PB Tregs
and subsequently expanded Treg
populations. Data points are mean
±SEM. (B) Fresh ileal resection
specimen opened longitudinally to
show ileal stricture (marked ‘S’) and
proximal inﬂamed, haemorrhagic
mucosa with deep ulceration (arrows).
Scale bar: 2 cm. (C) Representative
microscopic image from this resection
showing mucosal distortion, ulceration
(marked ‘U’) and transmural
inﬂammation, including lymphoid
aggregates (arrows). 12.5× H&E. Scale
bar: 2 mm. (D) Representative FACS
plots gated on live CD3+ events,
showing proliferation of MLN Tcons
cultured alone (top left panel) or with
Tregs at a 1:1 MLNMC:Treg ratio
(bottom left panel). Pooled data
showing Treg-mediated suppression of
MLN CD3+ proliferation (right panel,
n=5). Box and whisker plot shows
median, IQR and range. (E)
Representative FACS plots gated on
live MLN CD3+ events showing CD154
expression on MLN Tcons cultured alone
(top left panel) or with Tregs at a 1:1
MLNMC:Treg ratio (bottom left panel).
Pooled data showing Treg-mediated
suppression of CD154 expression in
live MLN CD3+ cells (right panel, n=5).
(F) Representative FACS plots gated on
live LP CD3+ events showing CD154
expression on LP Tcons cultured alone
(top left panel) or with Tregs at a 1:1
LPMC:Treg ratio (bottom left panel).
Pooled data showing Treg-mediated
suppression of CD154 expression in
live LP CD3+ cells (right panel, n=5).
(D–F) Dotted line shows non-speciﬁc
suppression from ‘2X control’.
Comparisons between observed
suppression and non-speciﬁc
suppression (†p<0.05, ††p<0.01,
†††p<0.001, ††††p<0.0001) and
observed suppression and no
suppression (zero, *p<0.05, **p<0.01,
***p<0.001 and ****p<0.0001) are
shown. Tregs, thymus-derived regulatory
T cells; MLN, Mesenteric lymph node;
LP, lamina propria; Tcons, conventional
CD4+CD25lo/int T cells; PB, peripheral
blood; FACS, ﬂuorescence-activated cell
sorting; MLNMC, MLN mononuclear
cell; LPMC, LP mononuclear cell; CTV,
Cell Trace Violet.
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at 96h25 49 Signiﬁcant dose-dependent suppression of CD154
expression in MLN and LP T cells was observed (ﬁgure 4E, F),
demonstrating that in vitro expanded D24 CD45RA+ Tregs sup-
press early activation of MLN and LP Tcons in vitro.
DISCUSSION
There remains an unmet need to develop novel therapies for
CD, as current drug treatments frequently fail to maintain long-
term remission and may be complicated by signiﬁcant side
effects. Cellular therapies are emerging as potentially attractive
therapeutic strategies. Tregs are effective in preclinical models of
colitis2 6 and phase 1 clinical trials suggest that in vitro
expanded Tregs are safe in the prophylaxis and treatment of
GvHD12 24 and type 1 diabetes.18 We built on recent work to
describe a method for isolation and expansion of Tregs from
Crohn’s blood that is readily transferable to a GMP background
and addresses several barriers to the use of expanded Tregs as an
autologous cell-based therapy in this important disease.
Tregs can be selected and expanded in vitro to clinically
useful numbers under both R&D-grade,11 13 16 21 23 26 and
GMP conditions12 18 24 retaining an in vitro suppressive func-
tion before infusion into humans. We showed that it is feasible
to do the same using Tregs obtained from Crohn’s blood, includ-
ing patients receiving thiopurines or anti-tumor necrosis factor
(TNF) medications. Even after prolonged culture, these Tregs
maintained FOXP3 expression and suppressed activation of
autologous T cells.
T cell lineage plasticity is well described. A major potential
barrier to Treg therapy is the possibility that these cells might adopt
an inﬂammatory phenotype and worsen inﬂammation on adoptive
transfer. Freshly isolated thymus-derived Tregs from both mice and
humans can express proinﬂammatory cytokines and transcription
factors (TF) canonical to effector CD4+ lineages, including
IL-1739–41 and IFN-γ,44 both of which are implicated in CD patho-
genesis. Indeed, IL-17+FOXP3+ Tregs have been identiﬁed in non-
inﬂamed human blood and lymphoid tissue,40 and inﬂamed
Crohn’s mucosa.43 While there is some evidence that plastic cyto-
kine and TF expression may license efﬁcient Treg homing to, and
suppression of, Th1-mediated and Th17-mediated inﬂamma-
tion,44 56 this may also lead to the generation of Tregs with an
effector phenotype that contribute to inﬂammation.
We and others have demonstrated that in vitro expanded Tregs
cultured in the presence of rapamycin have enhanced pheno-
typic stability.13 21 We show that as well as retaining their sup-
pressive capacity, CD45RA+ rTregs expanded from the blood of
patients with CD in the presence of rapamycin do not express
IL-17A or other Th17-related genes, even following exposure to
proinﬂammatory cytokines that they would likely meet in
inﬂamed intestinal mucosa. These data corroborate data from
Hoffmann et al17 47 in healthy controls, showing that expanded
CD45RA+ Tregs are resistant to the induction of proinﬂamma-
tory cytokines on stimulation and highly express CD62L and
CCR7, which are associated with phenotypic stability.
Freshly isolated CD45RA+ rTregs have an epigenetically stable
FOXP3 locus with extensive TSDR demethylation.46 TSDR
demethylation correlates with stable FOXP3 expression in
vitro50 and Treg-mediated protection from autoimmunity in
vivo57 in humans. However, the signiﬁcance of TSDR demethy-
lation for in vitro expanded Tregs is poorly understood. Barzaghi
et al57 recently described a cohort of patients with ‘Immune
dysregulation, Polyendocrinopathy, Enteropathy, X-linked syn-
drome (IPEX)-like syndrome’, severe multisystem autoimmunity
in the absence of identiﬁable mutations in molecules implicated
in Treg function, with decreased TSDR demethylation despite
normal Treg numbers and in vitro suppression. This suggests that
ex vivo expanded CD45RA− Tregs, with incomplete TSDR
demethylation, may have suboptimal biological activity in vivo,
despite suppressive function in vitro. These data also suggest
that CD45RA+ Tregs are more likely to retain phenotypic stabil-
ity and are less likely to acquire an effector phenotype than
CD45RA− Tregs, consistent with a more favourable safety proﬁle
of this Treg subset as a cell-based therapy for CD.
In order to be therapeutically effective, adoptively transferred
Tregs may need to trafﬁc to intestinal lymphoid tissue or LP.
Some groups have taken advantage of TCRs speciﬁc for luminal
antigens to direct Tregs to the intestinal mucosa, such as
IL-10-producing T cell clones with ovalbumin-speciﬁc TCRs,58
or T cells with transgenic Cbir1 ﬂagellin-speciﬁc TCRs.59
Alternatively, Treg expansion in the presence of ATRA induces
α4β7 integrin expression but also increases effector cytokine
expression, such as IL-17 and IFN-γ, potentially limiting its use
in GMP cell expansion.13 21 We show that CD45RA+ Tregs
expanded in the presence of IL-2 and rapamycin highly express
CD62L and CCR7, allowing homing to, and anatomical orien-
tation within lymphoid tissue.60 61 Treg CD62L expression is
also required for Treg-mediated cure of GvHD.
30 CD45RA+
Tregs also expressed CCR4, required for Treg-mediated preven-
tion of CD45RBhi colitis.62 Interestingly, murine Tregs do not
need to home to intestinal LP to prevent CD45RBhi adoptive
transfer colitis. β7 integrin-null Tregs home to MLN and prevent
colitis in this model, despite almost undetectable LP homing.63
Consequently, the ability to home to MLN is highly desirable in
potentially therapeutic cells.
CD45RA+ Tregs also express α4β7 integrin and CXC motif
receptor 3 (CXCR3), indicating an ability to home to LP and
sites of inﬂammation, respectively. Moreover, we used a human
small intestinal xenotransplant model to show, for the ﬁrst time,
that in vitro expanded CD45RA+ Tregs from patients with CD
home to inﬂamed human gut in vivo. Xenotransplanted SB seg-
ments develop into tissue that is morphologically and function-
ally identical to normal gut and is capable of peristalsis and
nutrient absorption.53 54 The xenografts also possess a chimeric
endothelium that expresses human MadCAM-1.64 This is the
ﬁrst demonstration that this model can be used in the assess-
ment of immune cell homing.
Xenograft-bearing mice received rhIL-2 in order to support
survival of adoptively transferred human Tregs,
23 as murine IL-2
is less efﬁcient at promoting proliferation of human T cells than
rhIL-2, despite cross-reactivity.65 As recent phase 1 trials of in
vitro expanded Tregs in GvHD and type 1 diabetes mellitus
showed signs of clinical efﬁcacy without supplemental rhIL-2, it
is likely that this is a feature of the experimental system and will
not be required in clinical trials in Inﬂammatory bowel disease
(IBD).12 18 24
Future work will include ‘humanising’ xenograft-bearing mice
and developing additional techniques to induce xenograft
inﬂammation, thus allowing us to assess the functional impact
of CD45RA+ Tregs on gut inﬂammation. The percentage of LP
human T cells that could be recovered from human bowel trans-
plants was relatively modest compared with the percentage of
T cells recovered from the spleen. Given that the expression
of the gut homing integrin α4β7 was only expressed on ∼20%
of the puriﬁed Tregs, future work may need to address methods
to increase α4β7 expression, such as the use of retinoic acid, as
we have previously shown.21
An additional barrier to Treg therapy in CD is that effector
T cells from the diseased mucosa of patients with CD may be
resistant to the suppressive action of Tregs. Indeed, we previously
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showed that Tcons isolated from inﬂamed Crohn’s mucosa are
relatively resistant to Treg-mediated suppression, due to overex-
pression of Smad7, an inhibitor of TGF-β signalling.35 36 In this
study, we utilised Tregs cultured in the presence of rapamycin,
which has been shown to enhance the suppressive ability of in
vitro expanded Tregs, compared with Tregs freshly isolated from
the same donor26 38 and show that in vitro expansion enhances
the suppressive ability of Tregs obtained from CD PB.
Rapamycin-expanded CD45RA+ Tregs effectively suppress both
MLN and LP T cells obtained from inﬂamed Crohn’s resection
specimens. These data suggest that in vitro expanded CD45RA+
Tregs may modulate immune responses in niches directly relevant
to the pathogenesis of CD. Tregs use multiple mechanisms to
suppress in vitro and in vivo, including contact-dependent
mechanisms (CTLA-4, perforin-granzyme B) and contact-
independent mechanisms (IL-10, TGF-β, extracellular ATPase
activity via CD39/CD73,etc). Sakaguchi et al10 has proposed a
multistep model of in vitro suppression that initially requires
cell-cell contact but is subsequently contact independent. The
mechanism of suppression of erstwhile ‘resistant’ mucosal Tcons
by in vitro expanded Tregs is currently unknown and will be the
subject of further study. In addition, not all of the patients in
this study had active disease, so it will be important to extend
these data further to broaden the therapeutic relevance of these
ﬁndings. However, a substantial proportion of the patients in
this study did have evidence of disease activity (n=5/13), which
did not affect either Treg expansion or function.
In conclusion, we have shown that in vitro expanded
CD45RA+ Tregs are likely to be the most suitable Treg subset for
cellular therapeutics in CD. This subset is readily expandable to
sufﬁciently high numbers under conditions that are readily
transferable to GMP, for clinical use. They express an appropri-
ate repertoire of homing receptors for MLN and gut, and effect-
ively trafﬁc to inﬂamed gut in vivo. As well as retaining
powerful suppressive properties, these cells show little or no
capacity for plasticity towards a potentially harmful effector
phenotype, which correlates with an epigenetically stable
FOXP3 locus. This study addresses many of the perceived bar-
riers to Treg cell treatment for CD and paves the way for a clin-
ical trial of in vitro expanded CD45RA+ Tregs in this
therapeutically challenging disease.
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